The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. (Q37784203)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Mohammad T. Alsuwaidan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sidney H. Kennedy

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

Roger S McIntyre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Ka Young Park

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Candy W Y Law

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Farah Sultan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Amanda Adams

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Maria Teresa Lourenco

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Aaron K S Lo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Hanna Woldeyohannes

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jinju Yoon

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

741-753

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11533280-000000000-00000

13 February 2020

exact match

0 references

cites work

Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

Depression and the course of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

Cardiovascular effects of bupropion in depressed patients with heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

Hypercortisolemic depression is associated with increased intra-abdominal fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

Safety and efficacy during long-term treatment with moclobemide

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11533280-000000000-00000

21 January 2018

12 December 2020

Imipramine and weight gain during the treatment of recurrent depression.

1 reference

12 December 2020

Associations between waist circumference and depressive disorders.

1 reference

12 December 2020

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

1 reference

12 December 2020

Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up

1 reference

12 December 2020

Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients

1 reference

12 December 2020

A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study

1 reference

12 December 2020

Diabetes mellitus in schizophrenic patients

1 reference

12 December 2020

Changes in weight during a 1-year trial of fluoxetine.

1 reference

12 December 2020

Monoamine oxidase inhibitors and weight gain.

1 reference

12 December 2020

Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study

1 reference

12 December 2020

Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age.

1 reference

12 December 2020

Weight gain with antidepressants and lithium

1 reference

12 December 2020

Are mood disorders and obesity related? A review for the mental health professional.

1 reference

12 December 2020

High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania.

1 reference

12 December 2020

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

12 December 2020

Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

1 reference

12 December 2020

Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment

1 reference

12 December 2020

Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting

1 reference

12 December 2020

Comorbidity in bipolar disorder: a framework for rational treatment selection

1 reference

12 December 2020

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

1 reference

12 December 2020

Weight gain. A side-effect of tricyclic antidepressants.

1 reference

12 December 2020

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

1 reference

12 December 2020

Fluoxetine in the treatment of obese type 2 diabetic patients.

1 reference

12 December 2020

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients

1 reference

12 December 2020

Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.

1 reference

12 December 2020

Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension

1 reference

12 December 2020

Family history of type 2 diabetes in schizophrenic patients

1 reference

12 December 2020

Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study

1 reference

12 December 2020

Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being.

1 reference

12 December 2020

Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial

1 reference

12 December 2020

Desvenlafaxine and weight change in major depressive disorder

1 reference

12 December 2020

Depression, the Metabolic Syndrome and Cardiovascular Risk

1 reference

12 December 2020

Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males

1 reference

12 December 2020

Changes in Weight During Treatment for Depression

1 reference

12 December 2020

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

1 reference

12 December 2020

Antidepressant-induced weight gain: a comparison study of four medications.

1 reference

12 December 2020

Glucocorticoids and insulin resistance: old hormones, new targets

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

The prevalence of metabolic syndrome among psychiatric inpatients in Brazil

1 reference

12 December 2020

Screening for type 2 diabetes

1 reference

12 December 2020

The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence?

1 reference

12 December 2020

The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients

1 reference

12 December 2020

Long-term efficacy and safety of bupropion

1 reference

12 December 2020

The effects of mirtazapine on plasma lipid profiles in healthy subjects.

1 reference

12 December 2020

Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes

1 reference

12 December 2020

Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus

1 reference

12 December 2020

Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine

1 reference

12 December 2020

Changes in appetite and weight during the pharmacological treatment of patients with panic disorder.

1 reference

12 December 2020

The emergence of triglycerides as a significant independent risk factor in coronary artery disease.

1 reference

12 December 2020

Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances

1 reference

12 December 2020

Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls.

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Effect of mirtazapine treatment on body composition and metabolism.

1 reference

12 December 2020

The P revention of R ecurrent E pisodes of Depression with Ven lafaxine for T wo Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases

1 reference

12 December 2020

Glucose dysregulation and mirtazapine-induced weight gain

1 reference

12 December 2020

Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes.

1 reference

12 December 2020

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

1 reference

12 December 2020

Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin study

1 reference

12 December 2020

Increased cholesterol levels during paroxetine administration in healthy men.

1 reference

12 December 2020

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

1 reference

12 December 2020

Comparison of bupropion and trazodone for the treatment of major depression.

1 reference

12 December 2020

THE XYLOSE METABOLISM IN DEPRESSED PATIENTS AND ITS ALTERATIONS UNDER THE INFLUENCE OF ANTIDEPRESSIVE HYDRAZINES

1 reference

12 December 2020

Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss

1 reference

12 December 2020

Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study

1 reference

12 December 2020

Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine.

1 reference

12 December 2020

Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion

1 reference

12 December 2020

Depression in diabetes: the chicken or the egg?

1 reference

12 December 2020

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

1 reference

12 December 2020

Increased serum total cholesterol to HDL-cholesterol ratio after imipramine.

1 reference

12 December 2020

Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors

1 reference

12 December 2020

Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo

1 reference

12 December 2020

African Women With Depression: The Effect of Imipramine and Fluoxetine on Body Mass Index and Leptin Secretion

1 reference

12 December 2020

Mood disorders and allostatic load

1 reference

12 December 2020

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

1 reference

12 December 2020

Immune dysregulation in major depression: a critical review of existing evidence

1 reference

12 December 2020

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

12 December 2020

Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity

1 reference

12 December 2020

The effects of isocarboxazid on blood pressure and pulse

1 reference

12 December 2020

The prevalence of comorbid depression in adults with diabetes: a meta-analysis

1 reference

12 December 2020

Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type

1 reference

12 December 2020

Hypertension and depression.

1 reference

12 December 2020

Imipramine and weight gain during the long-term treatment of recurrent depression

1 reference

12 December 2020

Inflammation, cardiovascular disease, and metabolic syndrome as sequelae of violence against women: the role of depression, hostility, and sleep disturbance

1 reference

12 December 2020

Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials

1 reference

12 December 2020

Excess mortality in bipolar and unipolar disorder in Sweden

1 reference

12 December 2020

Mortality of patients with mood disorders: follow-up over 34-38 years

1 reference

12 December 2020

Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications

1 reference

12 December 2020

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

1 reference

12 December 2020

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

12 December 2020

Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments

1 reference

12 December 2020

Prevalence of depression in adults with diabetes. An epidemiological evaluation

1 reference

12 December 2020

Metabolic issues and cardiovascular disease in patients with psychiatric disorders

1 reference

12 December 2020

The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection

1 reference

12 December 2020

Mirtazapine augmentation in the treatment of refractory depression.

1 reference

12 December 2020

Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting.

1 reference

12 December 2020

Cortisol circadian rhythm alterations in psychotic major depression

1 reference

12 December 2020

The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment

1 reference

12 December 2020

Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine.

1 reference

12 December 2020

Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report

1 reference

12 December 2020

Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.

1 reference

12 December 2020

The effect of desipramine on body weight in depression.

1 reference

12 December 2020

Cortisol activity and cognitive changes in psychotic major depression

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Depression and the heart: a systematic overview of definition, measurement, consequences and treatment of depression in cardiovascular disease

1 reference

12 December 2020

Treatment of obesity: need to focus on high risk abdominally obese patients

1 reference

12 December 2020

A randomized double-blind clinical trial of fluoxetine in obese diabetics

1 reference

12 December 2020

Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder.

1 reference

12 December 2020

Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism

1 reference

12 December 2020

Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary Artery Risk Development in Young Adults

1 reference

12 December 2020

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

1 reference

12 December 2020

Hypercortisolemia and hippocampal changes in depression.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

1 reference

12 December 2020

Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis.

1 reference

12 December 2020

Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment

1 reference

12 December 2020

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

1 reference

12 December 2020

Treatment of depression in diabetes: impact on mood and medical outcome

1 reference

12 December 2020

The making of a user friendly MAOI diet.

1 reference

12 December 2020

Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder

1 reference

12 December 2020

Depression and poor glycemic control: a meta-analytic review of the literature

1 reference

12 December 2020

The effect of antidepressants on lipid homeostasis: a cardiac safety concern?

1 reference

12 December 2020

Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study.

1 reference

12 December 2020

The Metabolic Syndrome in Patients With Severe Mental Illnesses

1 reference

12 December 2020

Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study

1 reference

12 December 2020

A report of trazodone-associated laboratory abnormalities

1 reference

12 December 2020

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

1 reference

12 December 2020

The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms

1 reference

12 December 2020

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

12 December 2020

Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy

1 reference

12 December 2020

Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap

1 reference

12 December 2020

Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment

1 reference

12 December 2020

Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment

1 reference

12 December 2020

Cardiovascular effects of fluvoxamine and maprotiline in depressed patients.

1 reference

12 December 2020

Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD Project.

1 reference

12 December 2020

Cytokines and psychopathology: lessons from interferon-alpha

1 reference

12 December 2020

Weight gain and antidepressants

1 reference

12 December 2020

Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy

1 reference

12 December 2020

Sertraline treatment of major depression in patients with acute MI or unstable angina

1 reference

12 December 2020

Depression and the metabolic syndrome: gender-dependent associations

1 reference

12 December 2020

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction.

1 reference

12 December 2020

The association between childhood depression and adulthood body mass index

1 reference

12 December 2020

Relationship between antidepressants and glycolipids in the forced swimming test in mice

1 reference

12 December 2020

Overview of managing medical comorbidities in patients with severe mental illness.

1 reference

12 December 2020

Depression and immune function: central pathways to morbidity and mortality

1 reference

12 December 2020

Changes in weight and glucose tolerance during treatment with mirtazapine

1 reference

12 December 2020

Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania.

1 reference

12 December 2020

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

Hypertriglyceridemia as a cardiovascular risk factor

1 reference

12 December 2020

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

1 reference

12 December 2020

The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms.

1 reference

12 December 2020

Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases

1 reference

12 December 2020

Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder

1 reference

12 December 2020

Metabolic syndrome and depression: a cross-sectional analysis.

1 reference

12 December 2020

Stress and the individual. Mechanisms leading to disease

1 reference

12 December 2020

An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.

1 reference

12 December 2020

Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study

1 reference

12 December 2020

Does treatment with duloxetine for neuropathic pain impact glycemic control?

1 reference

12 December 2020

Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study

1 reference

12 December 2020

Amitriptyline, weight gain and carbohydrate craving: a side effect.

1 reference

12 December 2020

Multicenter double-blind study of moclobemide and maprotiline

1 reference

12 December 2020

Recent evidence linking coronary heart disease and depression

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

1 reference

12 December 2020

10.2165/11533280-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806987%20AND%20SRC:MED&resulttype=core&format=json